Abstract: Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients).

Abstract: Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients).

Abstract: Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients). In some embodiments, provided herein are therapeutic devices comprising: (a) a vector encoding Sirtuin-1 (Sirt 1); and (b) a hydrogel carrier. In some embodiments, the vector comprises a viral vector comprising a polynucleotide sequence encoding Sirt 1. In some embodiments, the vector comprises a non-viral vector comprising a polynucleotide sequence encoding Sirt1.

Abstract: Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients). In some embodiments, provided herein are therapeutic devices comprising: (a) a vector encoding Sirtuin-1 (Sirt 1); and (b) a hydrogel carrier. In some embodiments, the vector comprises a viral vector comprising a polynucleotide sequence encoding Sirt 1. In some embodiments, the vector comprises a non-viral vector comprising a polynucleotide sequence encoding Sirt1.

Abstract: Compositions comprising endothelial cells (ECs) differentiated from induced pluripotent stem cells (iPSC)that over-express Sirtuin 1 (SIRT1) are disclosed. Further disclosed are methods of preparation of the compositions, and methods for treating a subject comprising administering transplatanbe cells, tissue, or organ comprising the iPSC-derived ECs overexpressing SIRT1, as well as methods of testing an agent for therapeutic efficacy and toxicity using the compositions.

Abstract: Trocar seal assemblies are disclosed which consist of a helically-shaped seal positioned within a trocar's cannula; wherein, as an instrument is inserted through the central bore of the helically-shaped seal, the helically-shaped seal expands, thereby increasing the diameter of the central bore. In other embodiments, a protective member is positioned within a retaining member; wherein the protective member is configured as a helix and, as an instrument is inserted through the central bore of the helix, the helix expands, thereby increasing the diameter of the central bore.

Abstract: Trocar seal assemblies are disclosed which consist of a protective member and a retaining member. The protective member prevents accidental perforations of the retaining member during the insertion of an instrument through the seal assembly and assists in forming a seal against the instrument when inserted in the seal assembly. The protective member is generally configured with a circular upper portion and a generally conical lower portion. The lower portion of the protective member consists of a plurality of flaps which increasingly overlap as they progress to the lower portion of the conical shape, thereby forming a seal at the lowest portion where the flaps overlap entirely. The overlapping flaps expand with minimal resistance when instruments are inserted through the seal assembly, thereby ensuring a proper seal regardless of the size or configuration of the instrument.